This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: primary healthcare

November 2019 Br J Cardiol 2019;26:130–2 doi:10.5837/bjc.2019.039

Depression screening in CAD may provide an opportunity to decrease health outcomes disparities

Adam Prince, Umair Ahmed, Nikhil Sharma, Rachel Bond

Abstract

Introduction Depression is a significant cause of morbidity and mortality in patients with coronary artery disease (CAD), with depressive symptoms affecting up to 45% of patients with CAD.1 Cardiac patients with depressive symptoms experience a 2 to 2.5-fold mortality increase when compared with cardiac patients without depressive symptoms.2 Screening tools include the patient health questionnaire (PHQ), which exists in two- and nine-question formats, with PHQ2 being nearly 90% sensitive and 73% specific for depression,3 and PHQ9 being 88% sensitive and 88% specific for depression.4 We examined the records of patients with CAD in an ambulato

| Full text
Diagnostic utility of real-time smartphone ECG in the initial investigation of palpitations

March 2018 doi:10.5837/bjc.2018.006

Diagnostic utility of real-time smartphone ECG in the initial investigation of palpitations

Anthony D Dimarco, Eunice N Onwordi, Conrad F Murphy, Emma J Walters, Lorraine Willis, Nicola J Mullan, Nicholas S Peters, Mark A Tanner

Abstract

(more…)

| Full text
Treatment of VTE in primary care: building a new approach to patient management with rivaroxaban

June 2015 Br J Cardiol 2015;22:78 doi:10.5837/bjc.2015.021

Treatment of VTE in primary care: building a new approach to patient management with rivaroxaban

Rosie Heath

Abstract

Introduction Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), causes considerable morbidity and mortality.1 VTE is associated with 370,000 deaths per year in the European Union (EU), an estimated 12% of annual deaths.1 The average incidence of VTE in Europe is approximately 160–180 per 100,000 person-years.1 Three large phase III trials with rivaroxaban, a direct factor Xa inhibitor approved for the treatment and prevention of VTE, have provided a strong safety and efficacy evidence base (table 1). The EINSTEIN-DVT study compared rivaroxaban (15 mg twice daily for 21 days, followed by 20 mg on

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now